Snapshots on Still’s: Short Expert Insights on the Management of Still’s Disease

These videos are promotional content funded by Sobi. 

Prescribing information may vary depending on local approval in each country. For full SmPC for Kineret please visit here. Before prescribing any product, always refer to the local materials such as the prescribing information and/or summary of product characteristics. 

To listen to the full podcasts as well as exploring other interesting podcasts click here https://thisiskineret.com/resources/.

In September 2024, the new EULAR/PReS recommendations on Still’s disease were published,¹ bringing key updates to diagnosis and management.  

Above, find clips from Bas Vastert (Paediatric Rheumatologist and Immunologist), and Eugen Feist (Adult Rheumatologist and Immunologist), where they address pressing questions that clinicians may have when putting these recommendations into practice.

Speakers

Bas Vastert
Pediatric Rheumatologist and Immunologist, UMC Utrecht, the Netherlands

Eugen Feist
Adult Rheumatologist and Immunologist, Klinik fur Rheumatologie und Klinische lmmunologie, Helios Fachklinik Vogelsang-Gommern GmbH, Gommern, Germany

Copyright: Sobi and Kineret are trademarks of Swedish Orphan Biovitrum, AB (publ) © 2025 Swedish Orphan Biovitrum AB (publ) – All rights reserved www.sobi.com 

Job code & DOP: PP-27225 April 2025

Reference 

1. Fautrel B et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Ann Rheum Dis. 2024;83:1614-27.